Brief: Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107
19/05/2022 14:43
May 19 (Reuters) - Fortress Biotech Inc FBIO.O :
* MUSTANG BIO ANNOUNCES UPDATED INTERIM DATA ON X-LINKED
SEVERE
COMBINED IMMUNODEFICIENCY TREATMENT WITH LENTIVIRAL VECTOR GENE
THERAPY SUPPORT UPCOMING MULTICENTER PIVOTAL PHASE 2 TRIAL FOR
MB-107
* MUSTANG BIO INC - ALL 23 TREATED PATIENTS ARE ALIVE AT
2.6-YEAR
MEDIAN FOLLOW-UP WITHOUT EVIDENCE OF MALIGNANT TRANSFORMATION
Source text for Eikon: ID:nGNX8Kw1mW
Further company coverage: FBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mustang Bio
See all newsAdvisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie